Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Mei-Yin C. Polley"'
Autor:
Zhi-Zhang Yang, Hyo Jin Kim, Jose C. Villasboas, Tammy Price-Troska, Shahrzad Jalali, Hongyan Wu, Rebecca A. Luchtel, Mei-Yin C. Polley, Anne J. Novak, Stephen M. Ansell
Publikováno v:
Cell Reports, Vol 26, Iss 8, Pp 2178-2193.e3 (2019)
Summary: Follicular lymphoma (FL) is an indolent B cell malignancy characterized by an extensive but poorly functional T cell infiltrate in the tumor microenvironment. Using mass cytometry, we identified at least 12 subsets of intratumoral CD4+ T cel
Externí odkaz:
https://doaj.org/article/f7deb86bdb074324b571a7c71eaaddce
Autor:
Rifaquat Rahman, Mei-Yin C Polley, Laura Alder, Priscilla K Brastianos, Carey K Anders, Hussein A Tawbi, Minesh Mehta, Patrick Y Wen, Susan Geyer, John de Groot, Gelareh Zadeh, Steven Piantadosi, Evanthia Galanis, Mustafa Khasraw
Publikováno v:
The Lancet Oncology. 24:e161-e171
Publikováno v:
American Society of Clinical Oncology Educational Book.
Advances in molecular profiling have led to improved understanding of glioma heterogeneity. Results have been used to inform diagnostic classification and targeted treatment strategies. Validation of these tests is necessary in the development of bio
Autor:
C. David James, David H. Gutmann, Hanlee Ji, Mitchel S. Berger, James M. Ford, David H. Rowitch, Paul G. Fisher, Mamie Yu, Mei-Yin C. Polley, Patrick Flaherty, Scott R. VandenBerg, J. Graeme Hodgson, Joshua D. Schiffman
Supplementary Table 1 from Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32ff7adb69ed66760cc14337013a288c
https://doi.org/10.1158/0008-5472.22385207
https://doi.org/10.1158/0008-5472.22385207
Autor:
C. David James, David H. Gutmann, Hanlee Ji, Mitchel S. Berger, James M. Ford, David H. Rowitch, Paul G. Fisher, Mamie Yu, Mei-Yin C. Polley, Patrick Flaherty, Scott R. VandenBerg, J. Graeme Hodgson, Joshua D. Schiffman
Supplementary Table 2 from Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4059266adfb5814011feb4b3fa6b48a
https://doi.org/10.1158/0008-5472.22385204
https://doi.org/10.1158/0008-5472.22385204
Autor:
C. David James, David H. Gutmann, Hanlee Ji, Mitchel S. Berger, James M. Ford, David H. Rowitch, Paul G. Fisher, Mamie Yu, Mei-Yin C. Polley, Patrick Flaherty, Scott R. VandenBerg, J. Graeme Hodgson, Joshua D. Schiffman
Malignant astrocytomas are a deadly solid tumor in children. Limited understanding of their underlying genetic basis has contributed to modest progress in developing more effective therapies. In an effort to identify such alterations, we performed a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::320fa9164dba5b1ad03806c4a4e74d58
https://doi.org/10.1158/0008-5472.c.6501152.v1
https://doi.org/10.1158/0008-5472.c.6501152.v1
Autor:
C. David James, David H. Gutmann, Hanlee Ji, Mitchel S. Berger, James M. Ford, David H. Rowitch, Paul G. Fisher, Mamie Yu, Mei-Yin C. Polley, Patrick Flaherty, Scott R. VandenBerg, J. Graeme Hodgson, Joshua D. Schiffman
Supplementary Figure 1 from Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15997cbbd0e20607e31ea100c62ea7ad
https://doi.org/10.1158/0008-5472.22385210.v1
https://doi.org/10.1158/0008-5472.22385210.v1
Autor:
Jonathan H. Shepherd, Karla Ballman, Mei-Yin C. Polley, Jordan D. Campbell, Cheng Fan, Sara Selitsky, Aranzazu Fernandez-Martinez, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Matthew G. Soloway, Patricia A. Spears, Baljit Singh, Sara M. Tolaney, George Somlo, Elisa R. Port, Cynthia Ma, Charles Kuzma, Eleftherios Mamounas, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Clifford A. Hudis, Eric P. Winer, Ann Partridge, Terry Hyslop, Lisa A. Carey, Charles M. Perou, William M. Sikov
Publikováno v:
Journal of Clinical Oncology. 40:1323-1334
PURPOSE CALGB 40603 ( NCT00861705 ), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete respon
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4), 934-935. American Society of Clinical Oncology
Autor:
Andrew B. Lassman, Khê Hoang-Xuan, Mei-Yin C. Polley, Alba A. Brandes, J. Gregory Cairncross, Johan M. Kros, Lynn S. Ashby, Martin J.B. Taphoorn, Luis Souhami, Winand N.M. Dinjens, Nadia N. Laack, Mathilde C.M. Kouwenhoven, Karen L. Fink, Pim J. French, David R. Macdonald, Denis Lacombe, Minhee Won, Thierry Gorlia, Minesh P. Mehta, Martin J. van den Bent
Publikováno v:
Journal of Clinical Oncology, 40(23), 2539-+. LIPPINCOTT WILLIAMS & WILKINS
Lassman, A B, Hoang-Xuan, K, Polley, M-Y C, Brandes, A A, Cairncross, J G, Kros, J M, Ashby, L S, Taphoorn, M J B, Souhami, L, Dinjens, W N M, Laack, N N, Kouwenhoven, M C M, Fink, K L, French, P J, Macdonald, D R, Lacombe, D, Won, M, Gorlia, T, Mehta, M P & van den Bent, M J 2022, ' Joint Final Report of EORTC 26951 and RTOG 9402 : Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 23, pp. 2539-2545 . https://doi.org/10.1200/JCO.21.02543
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(23), 2539-2545. American Society of Clinical Oncology
Lassman, A B, Hoang-Xuan, K, Polley, M-Y C, Brandes, A A, Cairncross, J G, Kros, J M, Ashby, L S, Taphoorn, M J B, Souhami, L, Dinjens, W N M, Laack, N N, Kouwenhoven, M C M, Fink, K L, French, P J, Macdonald, D R, Lacombe, D, Won, M, Gorlia, T, Mehta, M P & van den Bent, M J 2022, ' Joint Final Report of EORTC 26951 and RTOG 9402 : Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 23, pp. 2539-2545 . https://doi.org/10.1200/JCO.21.02543
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(23), 2539-2545. American Society of Clinical Oncology
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53489e4949cd8edc1b216438294271f2
http://hdl.handle.net/1887/3503820
http://hdl.handle.net/1887/3503820